Innate Pharma (IPH) Aktievy
Innate Pharma S.A. är ett bioteknikföretag som utvecklar immunterapier för cancerpatienter i Frankrike och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 1/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 0/6 |
| Utdelningar | 0/6 |
IPH Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Innate Pharma S.A. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | €1.80 |
| 52 veckors högsta | €2.20 |
| 52 veckors lägsta | €1.03 |
| Beta | 0.81 |
| 1 månads förändring | 43.08% |
| 3 månaders förändring | 28.02% |
| 1 års förändring | -8.54% |
| 3 års förändring | -35.02% |
| 5 års förändring | -42.16% |
| Förändring sedan börsintroduktionen | -62.73% |
Senaste nyheter och uppdateringar
IPH: 2026 Oncology Catalysts Will Drive Reassessment Of Risk Reward Profile
Analysts have lifted their price target on Innate Pharma to €8, citing a recalibrated risk profile, a slightly lower discount rate and updated expectations around revenue growth, profit margins and future P/E in light of what they describe as a crucial catalyst stretch for the company’s oncology pipeline through 2026. Analyst Commentary Analysts highlight that the updated €8 price target is closely linked to what they describe as a tight catalyst timeline through 2026.IPH: 2026 Oncology Readouts Will Define Upside Potential For This Catalyst Story
Narrative update overview Analysts have maintained a €4.50 price target for Innate Pharma, citing updated assumptions on discount rate, revenue, profit margins and future P/E, alongside upcoming 2026 oncology catalysts highlighted in recent Street research. Analyst Commentary Recent Street research frames Innate Pharma as a high-risk, event driven story into 2026, with attention centered on three oncology programs that analysts see as key to justifying current valuation assumptions.Recent updates
IPH: 2026 Oncology Catalysts Will Drive Reassessment Of Risk Reward Profile
Analysts have lifted their price target on Innate Pharma to €8, citing a recalibrated risk profile, a slightly lower discount rate and updated expectations around revenue growth, profit margins and future P/E in light of what they describe as a crucial catalyst stretch for the company’s oncology pipeline through 2026. Analyst Commentary Analysts highlight that the updated €8 price target is closely linked to what they describe as a tight catalyst timeline through 2026.IPH: 2026 Oncology Readouts Will Define Upside Potential For This Catalyst Story
Narrative update overview Analysts have maintained a €4.50 price target for Innate Pharma, citing updated assumptions on discount rate, revenue, profit margins and future P/E, alongside upcoming 2026 oncology catalysts highlighted in recent Street research. Analyst Commentary Recent Street research frames Innate Pharma as a high-risk, event driven story into 2026, with attention centered on three oncology programs that analysts see as key to justifying current valuation assumptions.IPH: Crucial 2026 Oncology Catalysts Are Expected To Unlock Long Term Upside
Analysts have trimmed their fair value estimate for Innate Pharma from about €6.10 to roughly €4.50, citing a reset in revenue growth expectations and a much higher assumed future P/E multiple, while also highlighting upcoming 2026 oncology catalysts as key to the story. Analyst Commentary Recent research has framed 2026 as an important test for Innate Pharma, with several oncology readouts and milestones clustered into what has been described as a crucial catalyst stretch.Earnings Update: Innate Pharma S.A. (EPA:IPH) Just Reported And Analysts Are Boosting Their Estimates
Investors in Innate Pharma S.A. ( EPA:IPH ) had a good week, as its shares rose 2.4% to close at €1.10 following the...
IPH: 2026 Oncology Catalysts Are Expected To Support Higher Future Multiple
Analysts have raised their price target on Innate Pharma to €8, citing a refreshed view of the company’s 2026 oncology catalyst lineup, including upcoming monalizumab PACIFIC-9 topline data, IPH4502 Phase 1 readout in solid tumors, and potential Phase 3 initiation for lacutamab pending financing. Analyst Commentary Recent commentary frames Innate Pharma as entering what some bullish analysts describe as a crucial catalyst stretch in 2026, with three oncology programs all lined up for key clinical events.IPH: Higher Margin Outlook Will Support Higher Future Earnings Multiple
Analysts have adjusted their price target on Innate Pharma, reflecting updated assumptions for the company’s discount rate, revenue growth outlook and future P/E. The new target is now set at €6.10, compared with the previous €6.10.IPH: Higher Margin Outlook Will Support Significantly Improved Future Earnings Multiple
Analysts have lifted their price target on Innate Pharma from €4.93 to €6.10, citing updated assumptions for revenue, profit margins and future P/E that together support a higher estimated fair value despite a slightly higher discount rate. Valuation Changes Fair Value: analyst estimate raised from €4.93 to €6.10, representing a sizeable upward revision in the implied share value.IPH: Updated Assumptions For Discount Rate Will Support Long Term Upside
Analysts have kept their price target for Innate Pharma broadly in line with prior views, with only a marginal adjustment reflecting updated assumptions on the discount rate, revenue growth and future P/E, rather than any major shift in conviction. Valuation Changes Fair Value: Kept unchanged at €6.10, indicating no alteration to the central valuation estimate.IPH: Upcoming Phase 3 CTCL Trial Will Support Long Term Upside Potential
Analysts have trimmed their price targets for Innate Pharma by a small amount, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower forward P/E, which together indicate a more measured view of the company’s risk and earnings profile. What's in the News The FDA completed its review of Innate Pharma's confirmatory Phase 3 protocol for lacutamab in cutaneous T cell lymphomas, with no further comments, clearing the TELLOMAK 3 trial to proceed (Key Developments).IPH: Regulatory Progress In Cutaneous T-Cell Lymphomas Will Drive Future Upside
Analysts have raised their price target for Innate Pharma, citing a higher fair value estimate of €6.10 per share compared with the prior €2.49. The revised estimate is supported by updated assumptions around revenue growth, profit margins, discount rate and future P/E.Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities
Analysts have raised Innate Pharma’s price target to €4.93 amid a refocused pipeline and higher risk concentration on antibody-drug conjugates, while cautioning that execution challenges, financing overhang, and lack of partnerships temper near-term confidence. Analyst Commentary Bearish analysts cite Innate Pharma's decision to deprioritize its proprietary antibody-based NK cell engager platform, which they believe overly concentrates the company’s pipeline risk onto its antibody-drug conjugate strategy.Innate Pharma S.A.'s (EPA:IPH) Popularity With Investors Is Under Threat From Overpricing
You may think that with a price-to-sales (or "P/S") ratio of 7.9x Innate Pharma S.A. ( EPA:IPH ) is a stock to avoid...
Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities
A robust pipeline of innovative oncology therapeutics and drug candidates highlights strong R&D productivity potentially leading to substantial future earnings.News Flash: Analysts Just Made A Notable Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts
Celebrations may be in order for Innate Pharma S.A. ( EPA:IPH ) shareholders, with the analysts delivering a...Revenues Not Telling The Story For Innate Pharma S.A. (EPA:IPH) After Shares Rise 26%
Innate Pharma S.A. ( EPA:IPH ) shares have continued their recent momentum with a 26% gain in the last month alone. The...Subdued Growth No Barrier To Innate Pharma S.A. (EPA:IPH) With Shares Advancing 37%
Innate Pharma S.A. ( EPA:IPH ) shares have had a really impressive month, gaining 37% after a shaky period beforehand...Risks To Shareholder Returns Are Elevated At These Prices For Innate Pharma S.A. (EPA:IPH)
It's not a stretch to say that Innate Pharma S.A.'s ( EPA:IPH ) price-to-sales (or "P/S") ratio of 4.1x right now seems...Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price
You may think that with a price-to-sales (or "P/S") ratio of 3.4x Innate Pharma S.A. ( EPA:IPH ) is definitely a stock...Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year
Innate Pharma S.A. ( EPA:IPH ) just released its latest annual results and things are looking bullish. The results were...Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher
Innate Pharma S.A. ( EPA:IPH ) shareholders will have a reason to smile today, with the analysts making substantial...Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates
Today is shaping up negative for Innate Pharma S.A. ( EPA:IPH ) shareholders, with the analysts delivering a...Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Aktieägarnas avkastning
| IPH | FR Biotechs | FR Marknad | |
|---|---|---|---|
| 7D | 8.4% | -2.4% | 1.5% |
| 1Y | -8.5% | 331.8% | -1.1% |
Avkastning vs industri: IPH presterade sämre än French Biotechs branschen som gav 331.8 % under det senaste året.
Avkastning vs Marknaden: IPH översteg French marknaden som gav -1.1 % under det senaste året.
Prisvolatilitet
| IPH volatility | |
|---|---|
| IPH Average Weekly Movement | 14.2% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in FR Market | 10.7% |
| 10% least volatile stocks in FR Market | 3.0% |
Stabil aktiekurs: IPH s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för French.
Volatilitet över tid: IPH s veckovolatilitet har ökat från 9% till 14% under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1999 | 164 | Jonathan Dickinson | www.innate-pharma.com |
Innate Pharma S.A. är ett bioteknikföretag som utvecklar immunterapier för cancerpatienter i Frankrike och internationellt. Bolagets produkter inkluderar Lacutamab (IPH4102), en anti-KIR3DL2-antikropp, som befinner sig i kliniska fas II-studier för behandling av kutant T-cells och perifert T-cellslymfom, samt i kliniska fas II-studier för behandling av refraktärt sézarysyndrom; Monalizumab, en immunkontrollpunktshämmare som befinner sig i kliniska fas III-studier för behandling av avancerade solida tumörer omfattande kolorektal- och lungcancer, samt huvud- och halscancer; IPH5201, en blockerande antikropp som befinner sig i klinisk fas II-studie och som riktar sig mot CD39s immunosuppressiva signalväg; IPH5301, en anti-CD73-antikropp som riktar sig mot den immunosuppressiva adenosinvägen för att främja antitumörimmunitet; IPH6401, en BCMA-riktad NK-cellaktiverare, och IPH6101, en NKp46-baserad NK-cellaktiverare som riktar sig mot CD123 i ett proprietärt multispecifikt antikroppsformat, samt IPH62, en B7-H3-riktad NK-cellaktiverare. Bolagets produkter i prekliniska studier är IPH43, en anti-MICA/B ADC och IPH45, en ADC (antibody drug conjugates), samt IPH67, en icke offentliggjord, multispecifik ANKET.
Innate Pharma S.A. Sammanfattning av grunderna
| IPH grundläggande statistik | |
|---|---|
| Börsvärde | €183.91m |
| Vinst(TTM) | -€49.18m |
| Intäkter(TTM) | €9.01m |
Är IPH övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| IPH resultaträkning (TTM) | |
|---|---|
| Intäkter | €9.01m |
| Kostnad för intäkter | €43.62m |
| Bruttovinst | -€34.61m |
| Övriga kostnader | €14.56m |
| Intäkter | -€49.18m |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
Sep 17, 2026
| Vinst per aktie (EPS) | -0.52 |
| Bruttomarginal | -384.40% |
| Nettovinstmarginal | -546.11% |
| Skuld/egenkapitalförhållande | -102.2% |
Hur har IPH utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/21 17:23 |
| Aktiekurs vid dagens slut | 2026/05/21 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Innate Pharma S.A. bevakas av 13 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Justin Zelin | BTIG |
| Suranjit Mukherjee | BTIG |
| Yigal Nochomovitz | Citigroup Inc |